Quantifying the thrombogenic potential of human plasma-derived immunoglobulin products
Tóm tắt
Từ khóa
Tài liệu tham khảo
Daniel, 2012, Immune globulins and thrombotic adverse events as recorded in a large administrative database in 2008 through 2010, Transfusion, 52, 2113, 10.1111/j.1537-2995.2012.03589.x
Orbach, 2005, Intravenous immunoglobulin: adverse effects and safe administration, Clin Rev Allergy Immunol, 29, 173, 10.1385/CRIAI:29:3:173
Radosevich, 2010, Intravenous immunoglobulin G: trends in production methods, quality control and quality assurance, Vox Sang, 98, 12, 10.1111/j.1423-0410.2009.01226.x
Dhainaut, 2013, In vitro and in vivo properties differ among liquid intravenous immunoglobulin preparations, Vox Sang, 104, 115, 10.1111/j.1423-0410.2012.01648.x
Ma, 2013, Quantitative determination of activated coagulation factor XI as an impurity in therapeutic immunoglobulins from Chinese blood fractionation companies, Genet Mol Res, 12, 2556, 10.4238/2013.January.4.17
Stoclin, 2013, Transfusion-related acute lung injury after intravenous immunoglobulin treatment in a lung transplant recipient, Vox Sang, 104, 175, 10.1111/j.1423-0410.2012.01645.x
Rizk, 2001, Transfusion-related acute lung injury after the infusion of IVIG, Transfusion, 41, 264, 10.1046/j.1537-2995.2001.41020264.x
Cohn, 1946, Preparation and properties of serum and plasma proteins. IV. A system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids, J Am Chem Soc, 68, 459, 10.1021/ja01207a034
Kistler, 1962, Large scale production of human plasma fractions. Eight years' experience with the alcohol fractionation procedure of Nitschmann, Kistler and Lergier, Vox Sang, 7, 414, 10.1111/j.1423-0410.1962.tb03274.x
Roemisch, 2011, Immunotherapy, 2, WMC002002
FDA (U.S. Food and Drug Administration), 2010
European Medicines Agency, 2010
European Medicines Agency, 2011
Funk, 2013, Thromboembolic events associated with immunoglobulin treatment, Vox Sang, 106, 54, 10.1111/vox.12025
Wolberg, 2000, Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations, Am J Hematol, 65, 30, 10.1002/1096-8652(200009)65:1<30::AID-AJH5>3.0.CO;2-J
Alving, 1980, Contact-activated factors: contaminants of immunoglobulin preparations with coagulant and vasoactive properties, J Lab Clin Med, 96, 334
Etscheid, 2011, Identification of kallikrein and FXIa as impurities in therapeutic immunoglobulins: implications for the safety and control of intravenous blood products, Vox Sang, 102, 40, 10.1111/j.1423-0410.2011.01502.x
FDA (U.S. Food and Drug Administration), 2011
Breitner-Ruddock, 2011, Laboratory investigations of intravenous immunoglobulin (IVIG) products associated with thromboembolic events
European Pharmacopoeia Commission – Council of Europe European Department for the Quality of Medicines, 2012
European Pharmacopoeia Commission – Council of Europe European Department for the Quality of Medicines, 2012
FDA (U.S. Food and Drug Administration), 2013
Sridhar, 2014, Immune globulins and same-day thrombotic events as recorded in a large health care database during 2008 to 2012, Transfusion, 10.1111/trf.12663
Marie, 2006, Intravenous immunoglobulin-associated arterial and venous thrombosis; report of a series and review of the literature, Br J Dermatol, 155, 714, 10.1111/j.1365-2133.2006.07390.x
Menis, 2013, Hyperimmune globulins and same-day thrombotic adverse events as recorded in a large healthcare database during 2008–2011, Am J Hematol, 88, 1035, 10.1002/ajh.23559
Lackner, 2014, Contamination of therapeutic human immunoglobulin preparations with apolipoprotein H (β2-glycoprotein I), Electrophoresis, 35, 515, 10.1002/elps.201300319
Duronio, 2007, Proposed relationship between intravenous immunoglobulin and thrombosis in renal transplant recipients, Ann Pharmacother, 41, 354, 10.1345/aph.1H434
Reinhart, 1992, Effect of high-dose intravenous immunoglobulin therapy on blood rheology, Lancet, 339, 662, 10.1016/0140-6736(92)90806-E
Baba, 2008, Effect of immunoglobulin therapy on blood viscosity and potential concerns of thromboembolism, especially in patients with acute Kawasaki disease, Recent Pat Cardiovasc Drug Discov, 3, 141, 10.2174/157489008784705359
Dalakas, 1994, High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events, Neurology, 44, 223, 10.1212/WNL.44.2.223
Stratta, 1997, Intravenous immunoglobulin contains detectable amounts of antiphospholipid antibodies, Br J Haematol, 96, 872
Thompson, 2012, One IVIG mystery solved, another demands vigilance, Am J Health Syst Pharm, 69, 271, 10.2146/news120012
Salge-Bartels, 2014, Significance of platelet and monocyte activation for therapeutic immunoglobulin-induced thromboembolism, Thromb Res, 133, 244, 10.1016/j.thromres.2013.11.026
Lebing, 2003, Properties of a new intravenous immunoglobulin (IGIV-C, 10%) produced by virus inactivation with caprylate and column chromatography, Vox Sang, 84, 193, 10.1046/j.1423-0410.2003.00285.x
Parkkinen, 2006, A modified caprylic acid method for manufacturing immunoglobulin G from human plasma with high yield and efficient virus clearance, Vox Sang, 90, 97, 10.1111/j.1423-0410.2005.00731.x
Wu, 2013, Dedicated removal of immunoglobulin (Ig)A, IgM, and factor (F)XI/activated FXI from human plasma IgG, Transfusion
Marzo, 2011, Quantitative determination of relevant amounts of blood coagulation factor XI activity in a specific brand of intravenous immunoglobulin, Immunotherapy, 5, WMC001922
Seligsohn, 2007, Factor XI in haemostasis and thrombosis: past, present and future, Thromb Haemost, 98, 84, 10.1160/TH07-04-0246
Jose, 2010, Pasteurization inactivates clotting enzymes during Flebogamma and Flebogamma Dif production, Immunotherapy, 1, WMC001425
Siegel, 2005, The product: all intravenous immunoglobulins are not equivalent, Pharmacotherapy, 25, 78S, 10.1592/phco.2005.25.11part2.78S
Komenda, 2014, Assessment of the ability of the Privigen® purification process to deplete thrombogenic factor XIa from plasma, Vox Sang, 10.1111/vox.12119
Turecek PL. Minimizing Procoagulant Impurities in IGIV Products Baxter's Approach FDA. U.S. Food and Drug Administration. Risk Mitigation Strategies to Address Potential Procoagulant Activity in Immune Globulin Products. Public Workshop; Rockville, MD, US. May 17–18, 2011.
Burnouf-Radosevich, 1992, A therapeutic highly purified factor XI concentrate from human plasma, Transfusion, 32, 861, 10.1046/j.1537-2995.1992.32993110761.x
Burnouf, 2001, Affinity chromatography in the industrial purification of plasma proteins for therapeutic use, J Biochem Biophys Methods, 49, 575, 10.1016/S0165-022X(01)00221-4
Grundmann, 2010, Modified thrombin generation assay: application to the analysis of immunoglobulin concentrates, Immunotherapy, 11, WMC001116
Liang, 2013, Correction of microplate location effects improves performance of the thrombin generation test, Thromb J, 11, 1, 10.1186/1477-9560-11-12
European Pharmacopoeia Commission – Council of Europe, 2008
Thomas, 1989, The relative antithrombotic effectiveness of heparin, a low molecular weight heparin, and a pentasaccharide fragment in an animal model, Thromb Haemost, 61, 204, 10.1055/s-0038-1646559
Wessler, 1959, Biologic assay of a thrombosis inducing activity in human serum, J Appl Physiol, 14, 943, 10.1152/jappl.1959.14.6.943
Gray, 2012
National Institute for Biological Standards and Control. WHO Reference Reagent, 1st International Reference Reagent for Activated Blood Coagulation Factor XI (FXIa), Human NIBSC code: 11/236. http://www.nibsc.org/products/biological_reference_materials/product_catalogue/detail_page.aspx?catid=11/236.
European Pharmacopoeia Commission - Council of Europe European Department for the Quality of Medicines, 2009
Roemisch, 2012, Comparison of thrombin generation assay (TGA) and non-activated partial thromboplastin time (NAPTT) for the assessment of enhanced procoagulant activity in immunoglobulin solutions, Immunotherapy, 3, WMC003247
Seifner, 2013, Assessment of immunoglobulin concentrates on thrombogenic activity by thrombin generation assay, prekallikrein activator assay, and size-exclusion chromatography, Transfusion, 10.1111/trf.12280
Putz M. Animal models – predictive value; Wessler and other models. FDA. U.S. Food and Drug Administration. Risk Mitigation Strategies to Address Potential Procoagulant Activity in Immune Globulin Products. Public Workshop; Rockville, MD, US. May 17–18, 2011.